181 related articles for article (PubMed ID: 33526000)
1. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report.
Nasso C; Sabbatini R; Baldessari C; Dominici M; Vitale MG
Tumori; 2021 Dec; 107(6):NP33-NP36. PubMed ID: 33526000
[TBL] [Abstract][Full Text] [Related]
2. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
5. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
[TBL] [Abstract][Full Text] [Related]
8. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
9. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
10. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
[TBL] [Abstract][Full Text] [Related]
16. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
17. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
19. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
[Next] [New Search]